CompletedNot Applicable

Serum Galectin-3 as a Marker of Human Papillomavirus Infection

Egypt100 participantsStarted 2021-12-01

Plain-language summary

This study aimed to assess the serum Galectin-3 levels in patients with warts both before and after cryotherapy and to investigate its potential contribution to the pathogenesis of human papillomavirus infection.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with non-genital warts.
✓. Age of patients: from 18 to 60 years.

Exclusion criteria

✕. Patients with genital and mucosal warts.
✕. Pregnancy and breastfeeding.
✕. Patients who received any wart treatment during the last month before enrollment in the study.

What they're measuring

Serum Galectin-3 levels assessment in patients with cutaneous warts.

Timeframe: 1 year

look at Galectin-3 serum level conceivable contribution to the aetiology of HPV infection, and determine how cryotherapy affected serum Galectin-3 levels.

Timeframe: 1 year

Trial details

NCT IDNCT06005389

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-01

View on ClinicalTrials.gov More Human Papillomavirus Infection trials